A retrospective cohort study on the protective effectiveness of influenza vaccine against influenza A among the individuals aged between 3‒17 years old in Fenghua District， Ningbo City from 2022 to 2023
10.19428/j.cnki.sjpm.2025.24725
- VernacularTitle:2022—2023年宁波市奉化区3~17岁人群流感疫苗接种对甲型流感保护效果的回顾性队列研究
- Author:
Yuqi SHAO
1
;
Weibo DONG
1
;
Yingping XIA
1
;
Chuan ZHANG
1
;
Yi LIU
1
Author Information
1. Fenghua District Center for Disease Control and Prevention, Ningbo, Zhejiang 315500, China
- Publication Type:Journal Article
- Keywords:
influenza A;
influenza vaccine;
protective effectiveness;
school-age children;
preschool children;
adolescent;
retrospective cohort study
- From:
Shanghai Journal of Preventive Medicine
2025;37(8):654-658
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo analyze the protective effect of different types of influenza vaccines (InfV) against influenza A among the individuals aged between 3‒17 years old, and to provide a scientific basis for the prevention and control of influenza in the future. MethodsA retrospective cohort study was conducted to collect data on the incidence and InfV vaccination of the individuals aged between 3‒17 years during the influenza epidemic season from 2022 to 2023. Vaccine effectiveness (VE) was calculated, and a log-binomial regression model was used to calculate the corrected VE. ResultsThe incidence rate of influenza in InfV vaccinated and un-vaccinated groups was 7.32% (1 937/ 26 446) and 9.65% (4 421/45 837), respectively. After adjusting for age and gender factors, the unadjusted VE (95%CI) was 54.57% (52.24%‒56.78%). The unadjusted VE (95%CI) was 53.66% (50.36%‒56.74%) for males and 55.60% (52.24%‒58.72%) for females, respectively. The unadjusted VE (95%CI) for the age group of 3‒ years, 6‒ years, 9‒ years, 12‒ years, and 15‒17 years were 64.08% (60.89%‒67.01%), 57.40% (53.71%‒60.80%), 57.77% (52.49%‒62.47%), 24.36% (9.49%‒36.79%), and 24.09% (-17.59%‒51.00%), respectively. The unadjusted VE (95%CI) for quadrivalent split-virion inactivated influenza vaccine, trivalent split-virion inactivated influenza vaccine, trivalent subunit influenza vaccine, and trivalent live attenuated influenza vaccine were 53.84% (51.32%‒56.24%), 62.17% (56.28%‒67.26%), 79.83% (69.94%‒86.46%), and 31.59% (19.07%‒42.18%), respectively. ConclusionThe InfV used during the 2022‒2023 influenza season had a good protective effect against influenza A among the individuals aged between 3‒17 years old, especially in those aged between 3‒11 years old.
